Publications

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.

Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.